CurrentEndo
Get Weekly

CurrentEndo coverage · page 2 of 5

The Lancet Diabetes & Endocrinology

Briefs 41–80 of 186 CurrentEndo has covered from this journal, newest publication first

Latest from The Lancet Diabetes & Endocrinology

All coverage, newest first

  1. Lancet Diabetes Endocrinol

    Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study

    Secondary analysisT2D & other

  2. Lancet Diabetes Endocrinol

    Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial

    Randomized controlled trialDiabetes in pregnancy

  3. Lancet Diabetes Endocrinol

    Thyroid cancer in adolescents and young adults: a population-based study in 185 countries worldwide

    Cohort studyEndocrine cancer

  4. Lancet Diabetes Endocrinol

    Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England

    Cohort studyT2D & other

  5. Lancet Diabetes Endocrinol

    Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden

    Cohort studyT2D & other

  6. Lancet Diabetes Endocrinol

    Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study

    Cohort studyT2D & other

  7. Lancet Diabetes Endocrinol

    Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework

    Guideline or statementT1D

  8. Lancet Diabetes Endocrinol

    Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

    Randomized controlled trialT2D & other

  9. Lancet Diabetes Endocrinol

    Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis

    Meta-analysisAdrenal

  10. Lancet Diabetes Endocrinol

    Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study

    Cohort studyAdrenal

  11. Lancet Diabetes Endocrinol

    Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis

    Meta-analysisT2D & other

  12. Lancet Diabetes Endocrinol

    Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial

    Randomized controlled trialObesity

  13. Lancet Diabetes Endocrinol

    Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial

    Randomized controlled trialT2D & other

  14. Lancet Diabetes Endocrinol

    Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial

    Randomized controlled trialObesity

  15. Lancet Diabetes Endocrinol

    Global, regional, and national cascades of diabetes care, 2000–23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study

    Meta-analysisT2D & other

  16. Lancet Diabetes Endocrinol

    Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data

    Cohort studyComplications

  17. Lancet Diabetes Endocrinol

    Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial

    Randomized controlled trialT2D & other

  18. Lancet Diabetes Endocrinol

    Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial

    Randomized controlled trialObesity

  19. Lancet Diabetes Endocrinol

    The central role of recovery of β-cell function in the remission of prediabetes: a prospective cohort study in Canada

    Cohort studyT2D & other

  20. Lancet Diabetes Endocrinol

    Prevalence and severity of symptoms across the menopause transition: cross-sectional findings from the Australian Women's Midlife Years (AMY) Study

    Cross-sectional studyReproductive endocrine

  21. Lancet Diabetes Endocrinol

    Non-autoimmune, insulin-deficient diabetes in children and young adults in Africa: evidence from the Young-Onset Diabetes in sub-Saharan Africa (YODA) cross-sectional study

    Cross-sectional studyT1D

  22. Lancet Diabetes Endocrinol

    Parental preconception BMI and risk of adverse birth outcomes in 8 million parent–child triads: a nationwide population-based cohort study in China

    Cohort studyObesity

  23. Lancet Diabetes Endocrinol

    Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis

    Meta-analysisDiabetes in pregnancy

  24. Lancet Diabetes Endocrinol

    Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

    Secondary analysisT2D & other

  25. Lancet Diabetes Endocrinol

    Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Randomized controlled trialObesity

  26. Lancet Diabetes Endocrinol

    Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial

    Randomized controlled trialTechnology

  27. Lancet Diabetes Endocrinol

    Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice

    Guideline or statementEndocrine cancer

  28. Lancet Diabetes Endocrinol

    Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis

    Meta-analysisEndocrine cancer

  29. Lancet Diabetes Endocrinol

    Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial

    Randomized controlled trialT2D & other

  30. Lancet Diabetes Endocrinol

    Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial

    Randomized controlled trialT2D & other

  31. Lancet Diabetes Endocrinol

    Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial

    Randomized controlled trialDiabetes in pregnancy

  32. Lancet Diabetes Endocrinol

    Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial

    Randomized controlled trialAdrenal

  33. Lancet Diabetes Endocrinol

    Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

    Guideline or statementEndocrine cancer

  34. Lancet Diabetes Endocrinol

    Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial

    Secondary analysisT2D & other

  35. Lancet Diabetes Endocrinol

    Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial

    Randomized controlled trialT2D & other

  36. Lancet Diabetes Endocrinol

    A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies

    Diagnostic or prognostic studyPituitary

  37. Lancet Diabetes Endocrinol

    Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies

    Meta-analysisDiabetes in pregnancy

  38. Lancet Diabetes Endocrinol

    Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

    Secondary analysisObesity

  39. Lancet Diabetes Endocrinol

    GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study

    Cohort studyT2D & other

  40. Lancet Diabetes Endocrinol

    Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

    Randomized controlled trialObesity

All 186 Briefs in ExploreShowing Briefs 41–80 of 186, newest first